Avecho Biotechnology (ASX: AVE) chief executive officer Dr Paul Gavin joins Small Caps to discuss the difference its proprietary drug delivery system TPM can make with various medicines to enhance injectable, oral and topical formulations for human health.

The company is developing its own cannabidiol soft-gel capsules with TPM technology as an over-the-counter treatment for insomnia.

Dr Gavin says Avecho’s strategy is to differentiate itself in the rapidly-growing multi-billion-dollar global medicinal cannabis market with its technology and formulations, which he says can offer significant therapeutic benefits as well commercial advantages.

Article:
https://smallcaps.com.au/avecho-biotechnology-targets-medicinal-cannabis-patented-drug-delivery-system/

For more information on Avecho Biotechnology:
https://smallcaps.com.au/stocks/AVE/

See omnystudio.com/listener for privacy information.